Abstract

Pancreatic islet transplantation is the fundamental treatment for insulin-dependent diabetes; however, donor shortage is a major hurdle in its use as a standard treatment. Accordingly, differentiated insulin-producing cells (DIPCs) are being developed as a new islet source. Differentiation efficiency could be enhanced if the spheroid structure of the natural islets could be recapitulated. Here, we fabricated DIPC spheroids using concave microwells, which enabled large-scale production of spheroids of the desired size. We prepared DIPCs from human liver cells by trans-differentiation using transcription factor gene transduction. Islet-related gene expression and insulin secretion levels were higher in spheroids compared to those in single-cell DIPCs, whereas actin–myosin interactions significantly decreased. We verified actin–myosin-dependent insulin expression in single-cell DIPCs by using actin–myosin interaction inhibitors. Upon transplanting cells into the kidney capsule of diabetic mouse, blood glucose levels decreased to 200 mg/dL in spheroid-transplanted mice but not in single cell-transplanted mice. Spheroid-transplanted mice showed high engraftment efficiency in in vivo fluorescence imaging. These results demonstrated that spheroids fabricated using concave microwells enhanced the engraftment and functions of DIPCs via actin–myosin-mediated cytoskeletal changes. Our strategy potentially extends the clinical application of DIPCs for improved differentiation, glycemic control, and transplantation efficiency of islets.

Highlights

  • Type 1 diabetes mellitus (T1DM) is characterized by insulin deficiency that results from the destruction of pancreatic islets, a phenomenon that is the result of an autoimmune response

  • The sizes of differentiated insulin-producing cells (DIPCs) spheroids were measured in suspension

  • The spheroid size consistently increased as the cell number increased, and an association was found with DIPCs (Pearson’s coefficient: 0.922)

Read more

Summary

Introduction

Type 1 diabetes mellitus (T1DM) is characterized by insulin deficiency that results from the destruction of pancreatic islets, a phenomenon that is the result of an autoimmune response (or other unknown causes). Due to the use of efficacious anti-rejection therapies and development of transplantation techniques, the long-term insulin-independence rate associated with clinical islet transplantation has improved [4,5]; donor shortage remains a major hurdle [6]. Insulin-producing cells (DIPCs)—differentiated from stem cells or adult cells—are being developed as a new islet source [7]. Somatic or adult stem cells with a non-pancreatic origin have been transdifferentiated into DIPCs directly through gene modifications [8,9,10,11]. These cells showed insulin production and genetic changes in vitro, they could not recapitulate physiological function in clinical applications

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call